Thursday, May 15, 2014

*New study attracting CRBCM attention:
Glembatumumab Vedotin in Metastatic Triple Negative Breast Cancer
(but comparison with Xeloda raises question, is this best in this disease?)

*Ramucirumab, and anti VEGF receptor 2, a noel antiangiogenic with role in Gastric cancer!
8mg/kg IV Q2weeks,  with or without taxanes....
Post a Comment